Over the past 10 years, scientists have made enormous progress in the understanding of the role of the microbial flora on health
This progress has led to the emergence of new therapeutic strategies based on the use of probiotics (defined as good bacteria), and more recently of postbiotics, a set of bioactive metabolites produced by probiotics. Silab became interested in these beneficial effects and applied its expertise in mastering natural and biotechnologies to bioguide the production of a natural postbiotic capable of addressing dry skin issues, using a biomimetic approach.
Microbiota is currently a major research topic as well as a therapeutic target. Probiotics have long been qualified as ‘good bacteria’ whose administration in a suitable quantity provides health benefits. This theory now seems to be evolving, however, being replaced by the notion of postbiotics, a set of bioactive metabolites produced by probiotics.1
In the continuity of its initial work on the cutaneous microbiota, Silab became interested in these postbiotics and drew inspiration from the adaptation properties to desert climate of a probiotic of plant origin (Lactobacillus arizonensis). Based on its recognised expertise in mastering natural, microbiota and biotechnologies, Silab used a targeted bioguiding technology resulting from a biomimetic approach. It led to the selective production of bioactive molecules (postbiotics) that constitute Lactobiotyl®, its novel active ingredient dedicated to dry skin.
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.